Literature DB >> 28687670

Stand-Alone Pulmonary Vein Isolation Versus Pulmonary Vein Isolation With Additional Substrate Modification as Index Ablation Procedures in Patients With Persistent and Long-Standing Persistent Atrial Fibrillation: The Randomized Alster-Lost-AF Trial (Ablation at St. Georg Hospital for Long-Standing Persistent Atrial Fibrillation).

Thomas Fink1, Michael Schlüter1, Christian-Hendrik Heeger1, Christine Lemes1, Tilman Maurer1, Bruno Reissmann1, Johannes Riedl1, Laura Rottner1, Francesco Santoro1, Boris Schmidt1, Peter Wohlmuth1, Shibu Mathew1, Christian Sohns1, Feifan Ouyang1, Andreas Metzner1, Karl-Heinz Kuck2.   

Abstract

BACKGROUND: Pulmonary vein isolation (PVI) for persistent atrial fibrillation is associated with limited success rates and often requires multiple procedures to maintain stable sinus rhythm. In the prospective and randomized Alster-Lost-AF trial (Ablation at St. Georg Hospital for Long-Standing Persistent Atrial Fibrillation), we sought to assess, in patients with symptomatic persistent or long-standing persistent atrial fibrillation, the outcomes of initial ablative strategies comprising either stand-alone PVI (PVI-only approach) or a stepwise approach of PVI followed by complex fractionated atrial electrogram ablation and linear ablation (Substrate-modification approach). METHODS AND
RESULTS: Patients were randomized 1:1 to stand-alone PVI or PVI plus substrate modification. The primary study end point was freedom from recurrence of any atrial tachyarrhythmia, outside a 90-day blanking period, at 12 months. A total of 124 patients were enrolled, with 118 patients included in the analysis (61 in the PVI-only group, 57 in the Substrate-modification group). Atrial tachyarrhythmias recurred in 28 PVI-only group patients and 24 Substrate-modification group patients, for 1-year freedom from tachyarrhythmia recurrence after a single ablation procedure of 54% (95% confidence interval, 43%-68%) in the PVI-only and 57% (95% confidence interval, 46%-72%) in the Substrate-modification group (P=0.86). Twenty-four patients in the PVI-only group (39%) and 18 in the Substrate-modification group (32%) were without arrhythmia recurrence and off antiarrhythmic drug therapy at the end of the 12-month follow-up.
CONCLUSIONS: In patients with persistent and long-standing persistent atrial fibrillation, no significant difference was observed in 12-month freedom from atrial tachyarrhythmias between an index ablative approach of stand-alone PVI and a stepwise approach of PVI plus complex fractionated atrial electrogram and linear ablation. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00820625.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  atrial fibrillation; catheter ablation; recurrence; tachycardia

Mesh:

Year:  2017        PMID: 28687670     DOI: 10.1161/CIRCEP.117.005114

Source DB:  PubMed          Journal:  Circ Arrhythm Electrophysiol        ISSN: 1941-3084


  30 in total

Review 1.  Approaches to Catheter Ablation of Nonparoxysmal Atrial Fibrillation.

Authors:  Jackson J Liang; Daniele Muser; Pasquale Santangeli
Journal:  Curr Treat Options Cardiovasc Med       Date:  2018-04-07

2.  Selecting persistent atrial fibrillation patients for pulmonary vein isolation based on the response to amiodarone: efficacy of the "one step back" strategy.

Authors:  Attila Benák; M Kohári; A Herczeg; A Makai; G Bencsik; L Sághy; R Pap
Journal:  J Interv Card Electrophysiol       Date:  2019-02-28       Impact factor: 1.900

3.  Vein of Marshall ethanol infusion for persistent atrial fibrillation: VENUS and MARS clinical trial design.

Authors:  Miguel Valderrábano; Leif E Peterson; Raquel Bunge; Michelle Prystash; Amish S Dave; Sherif Nagueh; Neal S Kleiman
Journal:  Am Heart J       Date:  2019-05-11       Impact factor: 4.749

4.  Treatment Planning for Atrial Fibrillation Using Patient-Specific Models Showing the Importance of Fibrillatory-Areas.

Authors:  Roya Kamali; Karli Gillete; Jess Tate; Devaki Abhijit Abhyankar; Derek J Dosdall; Gernot Plank; T Jared Bunch; Rob S Macleod; Ravi Ranjan
Journal:  Ann Biomed Eng       Date:  2022-08-05       Impact factor: 4.219

5.  Effect of Catheter Ablation With Vein of Marshall Ethanol Infusion vs Catheter Ablation Alone on Persistent Atrial Fibrillation: The VENUS Randomized Clinical Trial.

Authors:  Miguel Valderrábano; Leif E Peterson; Vijay Swarup; Paul A Schurmann; Akash Makkar; Rahul N Doshi; David DeLurgio; Charles A Athill; Kenneth A Ellenbogen; Andrea Natale; Jayanthi Koneru; Amish S Dave; Irakli Giorgberidze; Hamid Afshar; Michelle L Guthrie; Raquel Bunge; Carlos A Morillo; Neal S Kleiman
Journal:  JAMA       Date:  2020-10-27       Impact factor: 56.272

6.  Intraprocedural arrhythmia termination as an end point for hybrid ablation in patients with long-standing persistent atrial fibrillation: a 2-year follow-up study.

Authors:  Chen Tan; Li-Jun Zeng; Hai-Feng Shi; Ying Tian; Nan Ma; Hao Liu; Sheng-Chao Li; Xue-Hong Hu; Ju Mei; Xing-Peng Liu
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-06-28

7.  Extensive Left Atrial Low-Voltage Area During Initial Ablation is Associated with A Poor Clinical Outcome Even Following Multiple Procedures.

Authors:  Takashi Kanda; Masaharu Masuda; Mitsutoshi Asai; Osamu Iida; Shin Okamoto; Takayuki Ishihara; Kiyonori Nanto; Takuya Tsujimura; Yasuhiro Matsuda; Yosuke Hata; Hiroyuki Uematsu; Toshiaki Mano
Journal:  J Atr Fibrillation       Date:  2021-08-31

8.  Contact-Force Guided Posterior Wall Isolation as an Adjunctive Ablation Strategy for Persistent Atrial Fibrillation.

Authors:  Giusy Sirico; Domenico Sirico; Andrea Montisci; Enrico Cerrato; Martina Morosato; Stefania Panigada; Luca Ottaviano; Valerio De Sanctis; Massimo Mantica
Journal:  J Atr Fibrillation       Date:  2021-08-31

9.  Adjunctive Vein of Marshall Ethanol Infusion During Atrial Fibrillation Ablation: A Systematic Review and Meta-Analysis.

Authors:  Mohammed Mhanna; Azizullah Beran; Ahmad Al-Abdouh; Omar Sajdeya; Mohammed Altujjar; Modar Alom; Abdelrhman M Abumoawad; Ahmed M Elzanaty; Paul Chacko; Ehab A Eltahawy
Journal:  J Atr Fibrillation       Date:  2021-06-30

10.  Reconnection of Pulmonary Veins After Ablation. A Challenge to be Overcome.

Authors:  Silvia Helena Cardoso Boghossian; Ricardo Mourilhe-Rocha
Journal:  Arq Bras Cardiol       Date:  2021-07       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.